WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Tākaka man who died in mysterious circumstances namedUkraine lowers conscription age after drop in volunteers to fight Russian invasionLuxon says position on Treaty bill clear, but doesn't unequivocally rule it outNew Zealand is in a recession: What you need to knowMBIE calls on staff again to apply for voluntary redundanciesClose to 200kg of methamphetamine stopped from entering NZ, Australia marketLet's Get Wellington Moving project 'a bit of a disaster'Taiwan earthquake rescuers face threat of landslides, rockfalls as death toll at 12Live export ban petition passes 20,000 signatures, organiser wants five times thatPeregrine lander: Technical hitch threatens US Moon mission
1.6002s , 5260.578125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Planet Panorama news portal